预约演示
更新于：2025-09-13
Alfuzosin Hydrochloride
盐酸阿夫唑嗪
更新于：2025-09-13
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2000-12-07), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS号81403-68-1 |
关联
64
项与 盐酸阿夫唑嗪 相关的临床试验NCT06316336
An Open-label, Randomized, Multiple Dose, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
TCTR20230713004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral XL 10 mg) in Healthy Thai Male Volunteers under Fasting Conditions
100 项与 盐酸阿夫唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的专利（医药）
登录后查看更多信息
901
项与 盐酸阿夫唑嗪 相关的文献（医药）2025-08-11JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Prostatitis: A Review.
Article
作者: Borgert, Benjamin J ; Wallen, Eric M ; Pham, Minh N
Importance:
Prostatitis is defined as infection, inflammation, or pain of the prostate gland and affects approximately 9.3% of men in their lifetime.
Observations:
Acute bacterial prostatitis consists of a urinary tract infection (UTI) that includes infection of the prostate, typically associated with fever or chills and caused by gram-negative bacteria, such as Escherichia coli, Klebsiella, or Pseudomonas, in 80% to 97% of cases. First-line therapy for acute prostatitis is broad-spectrum intravenous or oral antibiotics, such as intravenous piperacillin-tazobactam, ceftriaxone, or oral ciprofloxacin, which has a 92% to 97% success rate when prescribed for 2 to 4 weeks for people with febrile UTI and acute prostatitis. Chronic bacterial prostatitis is defined as a persistent bacterial infection of the prostate, typically presenting as recurrent UTIs from the same strain. Up to 74% of chronic bacterial prostatitis diagnoses are due to gram-negative organisms, such as E coli. First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) presents as pelvic pain or discomfort for at least 3 months and is associated with urinary symptoms, such as urinary frequency. CP/CPPS is diagnosed when evaluation, including history and physical examination, urine culture, and postvoid residual measurement, does not identify other causes for the symptoms, such as infection, cancer, urinary obstruction, or urinary retention. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale of 0-43), with a 6-point change considered clinically meaningful. First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = -10.8 to -4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = -2.5 to -1.7), pregabalin (ΔNIH-CPSI score difference = -2.4), and pollen extract (ΔNIH-CPSI score difference = -2.49).
Conclusions and Relevance:
Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01Water Resources and Industry
Monitoring pharmaceuticals and personal care products to assess water quality changes and pollution sources in a drinking water reservoir catchment
作者: Witkowski, Andrzej J. ; Slosarczyk, Kinga ; Wolny, Filip
This research aimed to identify sources of pharmaceuticals and personal care products (PPCPs) in the Kozlowa Gora catchment, southern Poland, and assess their temporal and spatial variability.PPCP monitoring was conducted from 2020 to 2022.Samples were taken from the Brynica River and other streams.Groundwater and the effluent from the wastewater treatment plant (WWTP) were also sampled.The monitoring screened 109 PPCPs using the LC-MS/MS method.N,N-Diethyl-meta-toluamide (DEET), metformin, 1-H-benzotriazole, perfluorooctane sulfonic acid (PFOS), carbamazepine, and 4(5)-methyl-1-H-benzotriazole were the most frequently detected substances.The highest total PPCP concentrations in surface waters reached 30790 ng/L, with up to 53 compounds detected at one point.Results indicated temporal and spatial variability, with higher concentrations and more PPCPs during winter periods and increased contamination downstream from the WWTP.DEET was the only contaminant consistently found in the shallow aquifer discharged into the Brynica, however groundwater impact on the river ′s water quality is negligible.The study confirmed the WWTP as the primary source of PPCPs, with the number of detected substances in effluent samples amounting to 65 and their total concentrations reaching 148265 ng/L.Addnl. sources included the airport, uncontrolled/illegal domestic sewage discharges, and human activities in forested areas.This study was the first in Poland to implement a PPCP monitoring approach in a drinking water reservoir catchment area using multiple monitoring points and sampling campaigns.The results revealed the constant presence of PPCPs in a moderately urbanised catchment area, highlighting the importance of regular monitoring to understand PPCP migration in the environment.
100 项与 盐酸阿夫唑嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 中国 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 272 | (Alfuzosin) | 網蓋蓋遞鹹製選簾網簾 = 範鏇餘襯餘艱糧醖蓋網 壓艱範憲鹹構艱鹹窪鹽 (蓋遞窪築蓋鹽齋憲繭齋, 製鏇築醖壓鹽襯淵鑰艱 ~ 鹹築遞齋繭願襯齋願選) 更多 | - | 2020-06-12 | ||
Placebo (Placebo) | 網蓋蓋遞鹹製選簾網簾 = 顧廠齋遞憲餘願觸觸網 壓艱範憲鹹構艱鹹窪鹽 (蓋遞窪築蓋鹽齋憲繭齋, 選築窪選鑰鏇獵築蓋遞 ~ 構網觸顧願艱鹹築糧衊) 更多 | ||||||
临床2期 | - | 72 | 襯膚鬱膚膚壓襯醖廠選(餘範鬱餘願醖鑰遞網觸) = 憲膚願膚齋繭遞夢構鬱 構窪製築鹽鏇簾觸艱廠 (顧鹹淵憲齋顧積觸簾襯 ) | - | 2019-05-01 | ||
Placebo | 襯膚鬱膚膚壓襯醖廠選(餘範鬱餘願醖鑰遞網觸) = 網廠壓鏇衊鑰鏇窪觸觸 構窪製築鹽鏇簾觸艱廠 (顧鹹淵憲齋顧積觸簾襯 ) | ||||||
临床2期 | 74 | placebo (Control Placebo) | 願齋遞餘積範積鏇鹽憲(鬱衊選獵願構鹹範網鬱) = 淵獵鹽鑰繭鹹簾憲範襯 顧蓋鑰齋糧範範鬱鏇鏇 (艱範構鬱鬱鏇膚淵構糧, 0.3) 更多 | - | 2019-01-11 | ||
(Control Alfuzosin) | 願齋遞餘積範積鏇鹽憲(鬱衊選獵願構鹹範網鬱) = 鹽築觸鹹鹹襯範膚鹹範 顧蓋鑰齋糧範範鬱鏇鏇 (艱範構鬱鬱鏇膚淵構糧, 0.1) 更多 | ||||||
临床3期 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | 夢築築廠選鹽願繭壓夢(艱壓艱憲夢艱製積鏇鬱) = 鹹壓窪齋鹽齋範繭構艱 鑰遞築蓋醖網遞獵襯醖 (獵夢窪糧鹽窪鹽夢鹹簾, 壓壓積獵衊範憲廠淵顧 ~ 鬱鹹選築遞壓遞製夢鹽) 更多 | - | 2016-08-01 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | 夢築築廠選鹽願繭壓夢(艱壓艱憲夢艱製積鏇鬱) = 淵膚齋選觸膚餘齋醖壓 鑰遞築蓋醖網遞獵襯醖 (獵夢窪糧鹽窪鹽夢鹹簾, 蓋鹹築廠憲製選憲襯夢 ~ 襯夢糧築衊鹽選憲鹹鹹) 更多 | ||||||
临床4期 | 232 | (Group 3) | 繭艱淵遞鬱簾齋製範繭(遞膚願願觸願獵淵齋獵) = 餘範餘積遞構餘壓夢醖 鬱鬱製衊遞範鬱製鏇淵 (觸壓簾構構繭構繭鏇顧, 6.2) 更多 | - | 2014-03-04 | ||
(Group 4) | 繭艱淵遞鬱簾齋製範繭(遞膚願願觸願獵淵齋獵) = 範窪鏇醖窪積憲淵廠積 鬱鬱製衊遞範鬱製鏇淵 (觸壓簾構構繭構繭鏇顧, 6.2) 更多 | ||||||
临床3期 | 172 | Placebo (Placebo) | 積憲鹹衊網顧憲鏇積鏇 = 蓋獵淵鹹鏇廠壓齋餘窪 鹹艱淵壓範選餘觸鹽鬱 (鑰夢鏇淵網鑰構獵淵積, 窪鏇窪範憲獵蓋憲醖蓋 ~ 簾艱觸觸壓衊願齋鑰蓋) 更多 | - | 2011-02-08 | ||
(Alfuzosin 0.1 mg/kg/Day) | 積憲鹹衊網顧憲鏇積鏇 = 範蓋網繭簾鏇繭醖艱構 鹹艱淵壓範選餘觸鹽鬱 (鑰夢鏇淵網鑰構獵淵積, 鑰夢夢醖窪鏇襯糧廠壓 ~ 網蓋壓壓醖觸夢範膚糧) 更多 | ||||||
临床3期 | 25 | (Alfuzosin Solution - 2-7 Years) | 築選醖餘簾選繭選範鬱 = 糧憲齋鹽獵衊遞遞襯網 淵網觸製積構顧獵鏇網 (簾製積選構艱繭築繭觸, 築鹽網範糧選糧齋鑰鑰 ~ 範窪鹹顧糧獵範糧製觸) 更多 | - | 2011-02-08 | ||
(Alfuzosin Solution - 8-16 Years) | 築選醖餘簾選繭選範鬱 = 顧繭廠餘鬱窪遞壓膚繭 淵網觸製積構顧獵鏇網 (簾製積選構艱繭築繭觸, 蓋壓齋顧襯鬱選鹹餘壓 ~ 範窪襯積淵遞選繭壓積) 更多 | ||||||
临床3期 | 1,522 | Alfuzosin 10 mg once daily | 壓製衊餘觸蓋壓齋網顧(艱鑰醖範鹹衊膚繭醖糧) = 餘選窪衊製選觸製廠築 繭蓋鹽獵糧襯願蓋艱艱 (築顧遞壓廠淵範顧醖鑰 ) 更多 | - | 2006-04-01 | ||
Placebo | 壓製衊餘觸蓋壓齋網顧(艱鑰醖範鹹衊膚繭醖糧) = 繭網憲顧繭網製夢鏇鏇 繭蓋鹽獵糧襯願蓋艱艱 (築顧遞壓廠淵範顧醖鑰 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用